Literature DB >> 16011838

Applications of mouse glioma models in preclinical trials.

Xiaoyi Hu1, Eric C Holland.   

Abstract

Gliomas are the most common primary tumors that arise from glial cells and their precursors in the central nervous system. Most of the genetic alterations identified in human gliomas result in signal transduction abnormalities or disruption of cell cycle arrest pathways. Over the past years, several mouse glioma models have been generated based on human genetic abnormalities and the induced gliomas exhibit histological similarities to their human counterparts. There is emerging evidence suggesting that an oncogenic signaling initiating tumorigenesis is also required for tumor maintenance, these glioma models can be used to further characterize the mechanisms of oncogenic signaling in tumor formation, as well as identify molecular targets in preclinical trials.

Entities:  

Mesh:

Year:  2005        PMID: 16011838     DOI: 10.1016/j.mrfmmm.2004.08.023

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  15 in total

Review 1.  Roles of NG2 glial cells in diseases of the central nervous system.

Authors:  Jian-Ping Xu; Jie Zhao; Shao Li
Journal:  Neurosci Bull       Date:  2011-12       Impact factor: 5.203

Review 2.  The art of gene therapy for glioma: a review of the challenging road to the bedside.

Authors:  Alex Tobias; Atique Ahmed; Kyung-Sub Moon; Maciej S Lesniak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-09-19       Impact factor: 10.154

Review 3.  Drosophila melanogaster as a model system for human brain cancers.

Authors:  Renee D Read
Journal:  Glia       Date:  2011-05-02       Impact factor: 7.452

4.  Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model.

Authors:  Tiffany Doucette; Ganesh Rao; Yuhui Yang; Joy Gumin; Naoki Shinojima; B Nebiyou Bekele; Wei Qiao; Wei Zhang; Frederick F Lang
Journal:  Neoplasia       Date:  2011-08       Impact factor: 5.715

5.  SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.

Authors:  Kun-Wei Liu; Haizhong Feng; Robert Bachoo; Andrius Kazlauskas; Erin M Smith; Karen Symes; Ronald L Hamilton; Motoo Nagane; Ryo Nishikawa; Bo Hu; Shi-Yuan Cheng
Journal:  J Clin Invest       Date:  2011-03       Impact factor: 14.808

6.  Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.

Authors:  Michelle S Bradbury; Dolores Hambardzumyan; Pat B Zanzonico; Jazmin Schwartz; Shangde Cai; Eva M Burnazi; Valerie Longo; Steven M Larson; Eric C Holland
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

Review 7.  A role for the NG2 proteoglycan in glioma progression.

Authors:  William B Stallcup; Feng-Ju Huang
Journal:  Cell Adh Migr       Date:  2008-07-13       Impact factor: 3.405

8.  A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion.

Authors:  Laura M Shelton; Purna Mukherjee; Leanne C Huysentruyt; Ivan Urits; Joshua A Rosenberg; Thomas N Seyfried
Journal:  J Neurooncol       Date:  2010-01-13       Impact factor: 4.130

Review 9.  Platelet-derived growth factor receptor alpha in glioma: a bad seed.

Authors:  Kun-Wei Liu; Bo Hu; Shi-Yuan Cheng
Journal:  Chin J Cancer       Date:  2011-09

10.  Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.

Authors:  Brenda Auffinger; Atique U Ahmed; Maciej S Lesniak
Journal:  Front Oncol       Date:  2013-02-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.